复方苦参注射液减轻胃肠道肿瘤化疗毒副反应的分析-analysis of compound sophora flavescens injection in relieving side effects of chemotherapy on gastrointestinal tumors.docx

复方苦参注射液减轻胃肠道肿瘤化疗毒副反应的研究中文摘要目的：观察复方苦参注射液对胃肠道肿瘤患者化疗毒副反应的影响，探索苦参类药物对化疗的减毒功能。方法：应用简单数字分组原则，将80例有明确病理诊断的原发性胃肠道肿瘤术后患者随机分成两组（各40例），实验组及对照组均给予奥沙利铂+氟尿嘧啶+亚叶酸钙（FOLFOX4方案）化疗，并常规给予胃复安止吐。实验组化疗期间加用复方苦参注射液12ml静脉注射，1次/天,共5天。对照组单纯化疗。观察化疗期间患者的胃肠道反应情况及化疗后骨髓抑制情况。结果：实验组化疗后白细胞计数4.18±0.933109/L，明显高于对照组3.65±0.633109/L，两组统计学差异（P＜0.05）；实验组化疗后血小板163±44.73109/L，与对照组156±49.63109/L，比较两组无差异（P＞0.05）。实验组胃肠道反应的发生率为60.00%（24/40），而对照组为82.50%(33/40)，两组比较有差异（P＜0.05）。结论：复方苦参注射液能减轻化疗后骨髓抑制和减少胃肠道反应，为临床化疗辅助用药提供选择。关键词：复方苦参注射液；胃肠道肿瘤；毒副反应；骨髓抑制；胃肠道反应TheresearchofcompoundsophorainjectionreducingthesideeffectsofchemotherapyofgastrointestinaltumorAbstractObjective:Toevaluatetoxicandsideeffectsinthechemotherapyofgastroenterictumorpatientsofacceptingcompoundsophorainjection.Methods:80caseswithprimarygastrointestinalmalignanttumorwererandomlydividedintotwogroups(eachgroup,n=40).allpatientsweretreatedwithchemotherapyincludingoxaliplatin,fluorouracilandcalciumfoliate(FOLFOX4project)andwithmetoclopramidecommonly.Theexperimentalgroupwasreceivedintravenousinfusionof12mlcompoundsophorainjectionadditionallyduringtheperiodofchemotherapy,onceaday,5days.Thecontrolgroupwastreatedwithchemotherapyalone.Thegastrointestinalreactionduringtheperiodofchemotherapyandmyelosuppressionafterchemotherapywereobserved.Results:Theleukocytecount（4.18±0.933109/L）intheexperimentalgroupafterchemotherapyissignificantlyhigherthanthecontrolgroup（3.65±0.633109/L）.Therewasstatisticallysignificantdifferencebetweentwogroups(P0.05).Theplateletscount（163+3109/L）oftheexperimentalgroupafterchemotherapy,comparedwiththecontrolgroup（156+49.63109/L）hasnosignificantdifference(P0.05).Theincidenceofgastrointestinalreactionintheexperimentalgroupwas60.00%(24/40)ascomparedwith82.50%(33/40)ofthecontrolgroup,andthedifferenceswerestatisticallysignificant(P0.05).Conclusion:Compoundsophorainjectioncouldreducemyelosuppressionandgastrointestinalreactioncausedbychemotherapy,providechoiceforclinicaladjuvantchemotherapy.Keywords:compoundsophorainjection;gastroenterictumor;toxican